Choreo LLC Cuts Stake in Stryker Corporation $SYK

Choreo LLC cut its stake in shares of Stryker Corporation (NYSE:SYK) by 13.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,956 shares of the medical technology company’s stock after selling 1,645 shares during the quarter. Choreo LLC’s holdings in Stryker were worth $3,449,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Ascent Group LLC grew its position in Stryker by 17.1% during the 2nd quarter. Ascent Group LLC now owns 15,162 shares of the medical technology company’s stock valued at $4,774,000 after purchasing an additional 2,211 shares during the last quarter. Summit Securities Group LLC increased its position in shares of Stryker by 1,296.5% during the second quarter. Summit Securities Group LLC now owns 796 shares of the medical technology company’s stock valued at $251,000 after acquiring an additional 739 shares in the last quarter. TCW Group Inc. raised its holdings in Stryker by 1.8% in the 2nd quarter. TCW Group Inc. now owns 6,084 shares of the medical technology company’s stock worth $1,915,000 after acquiring an additional 109 shares during the last quarter. Marco Investment Management LLC increased its holdings in shares of Stryker by 1.5% in the 2nd quarter. Marco Investment Management LLC now owns 57,471 shares of the medical technology company’s stock worth $18,094,000 after purchasing an additional 834 shares in the last quarter. Finally, Elyxium Wealth LLC purchased a new position in shares of Stryker in the second quarter worth $206,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

SYK stock opened at $338.80 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The company has a market cap of $129.95 billion, a P/E ratio of 35.11, a price-to-earnings-growth ratio of 2.17 and a beta of 0.76. The stock’s fifty day moving average price is $324.61 and its 200-day moving average price is $333.57.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.

Insider Activity

In related news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

SYK has been the topic of a number of research analyst reports. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a report on Friday, May 1st. UBS Group started coverage on shares of Stryker in a research note on Tuesday, July 28th. They set a “buy” rating and a $400.00 target price on the stock. JPMorgan Chase & Co. dropped their price target on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Finally, Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.